Centessa Pharmaceuticals (NASDAQ:CNTA) Lowered to “Sell” Rating by Wall Street Zen

Centessa Pharmaceuticals (NASDAQ:CNTA) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

A number of other equities research analysts also recently issued reports on the stock. Truist Financial started coverage on shares of Centessa Pharmaceuticals in a research report on Monday, July 21st. They issued a “buy” rating and a $30.00 target price for the company. Oppenheimer started coverage on Centessa Pharmaceuticals in a report on Thursday, May 8th. They set an “outperform” rating and a $6.00 price objective for the company. Needham & Company LLC started coverage on Centessa Pharmaceuticals in a report on Wednesday, May 28th. They set a “buy” rating and a $35.00 price objective for the company. Finally, Chardan Capital reiterated a “buy” rating and set a $30.00 price objective on shares of Centessa Pharmaceuticals in a report on Tuesday. One analyst has rated the stock with a sell rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $28.10.

Centessa Pharmaceuticals Stock Up 2.3%

Shares of Centessa Pharmaceuticals stock opened at $18.05 on Friday. The stock has a 50-day moving average price of $14.76 and a 200 day moving average price of $14.51. The company has a market cap of $2.42 billion, a P/E ratio of -10.08 and a beta of 1.48. The company has a current ratio of 10.11, a quick ratio of 14.37 and a debt-to-equity ratio of 0.32. Centessa Pharmaceuticals has a 1 year low of $9.60 and a 1 year high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.03). As a group, analysts expect that Centessa Pharmaceuticals will post -1.6 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Gregory M. Weinhoff sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $15.56, for a total value of $155,600.00. Following the completion of the sale, the insider directly owned 122,279 shares in the company, valued at approximately $1,902,661.24. The trade was a 7.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Monday, July 21st. The shares were sold at an average price of $15.92, for a total transaction of $875,600.00. Following the completion of the transaction, the chief executive officer directly owned 221,017 shares in the company, valued at approximately $3,518,590.64. This represents a 19.93% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 236,322 shares of company stock worth $3,300,064. Insiders own 7.09% of the company’s stock.

Institutional Trading of Centessa Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. GF Fund Management CO. LTD. bought a new position in Centessa Pharmaceuticals in the 4th quarter worth $31,000. Caitong International Asset Management Co. Ltd increased its stake in shares of Centessa Pharmaceuticals by 15,209.5% in the first quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company’s stock worth $46,000 after purchasing an additional 3,194 shares during the period. Osterweis Capital Management Inc. bought a new position in shares of Centessa Pharmaceuticals in the first quarter worth about $47,000. Barclays PLC increased its stake in shares of Centessa Pharmaceuticals by 1,414.9% in the fourth quarter. Barclays PLC now owns 5,302 shares of the company’s stock worth $89,000 after purchasing an additional 4,952 shares during the period. Finally, Bank of New York Mellon Corp bought a new position in Centessa Pharmaceuticals in the 1st quarter worth approximately $147,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.